# US 2020/0392118 A1 · Disubstituted pyrazole compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392118 A1
- Document ID: US20200392118A1
- Status: Published application
- Kind: A1
- Application number: 16/902,806
- Filed: 2020-06-16
- Published: 2020-12-17
- Earliest claimed: 2019-06-17
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: David Andrew COATES; Timothy Barrett DURHAM; Richard Duane JOHNSTON; Steven Marc MASSEY; Patrick Gianpietro SPINAZZE; Douglas Richard STACK; James Lee TOTH
- Web page: https://patentgrep.com/patent/US20200392118A1

## CPC

- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 13/12: of the kidneys
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

## Claims

### Claim 1

A compound of the formula:
wherein
X is N, or C substituted with CN;
R is selected from: H,
R2 and R3 are both H, or one is H and the other is OH;
R4, R5, R6, R7 and R9 are independently H or CH3;
R8 is H, CH3, CH2CH2OH, C(═O)CH2NHz, or C(═O)CH3; and
R10 is OH or NH2;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein X is N, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein X is C substituted with CN, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The compound, or pharmaceutically acceptable salt thereof, according to claim 6, which is a succinate salt.

### Claim 8 (depends on 1)

A method of treating type 2 diabetes mellitus in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A method of treating heart failure in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A method of treating diabetic kidney disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A method of treating non-alcoholic steatohepatitis in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 6)

A method of treating type 2 diabetes mellitus in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6,
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 6)

A method of treating heart failure in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6,
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 6)

A method of treating diabetic kidney disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6,
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 6)

A method of treating non-alcoholic steatohepatitis in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of claim 6,
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition, comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients.

### Claim 17 (depends on 1)

A process for preparing a pharmaceutical composition, comprising admixing a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients.
